Dean Rudge's profile photo

Dean Rudge

Birmingham

Deputy Editor at Generics Bulletin

Assistant editor at Generics bulletin

Featured in: Favicon informa.com (+4) Favicon manchestereveningnews.co.uk Favicon walesonline.co.uk Favicon birminghammail.co.uk Favicon liverpoolecho.co.uk Favicon chroniclelive.co.uk Favicon coventrytelegraph.net Favicon bristolpost.co.uk Favicon hulldailymail.co.uk Favicon football.london

Articles

  • Shilpa Stumbles On Lenvima Challenge And Faces Wait Until 2036

    3 days ago | insights.citeline.com | Dean Rudge

    Shilpa Stumbles On Lenvima Challenge And Faces Wait Until 2036Indian Firm Had Challenged Eisai’s US Patent For ‘Highly Pure Lenvatinib Mesylate’Generic competition to Eisai’s oral-dose blockbuster cancer therapy Lenvima is set to materialize in the US in 2030 – however, for now, that won’t be from ANDA filer Shilpa Medicare.

  • ‘Why Wouldn’t You Use This?’: Teva Plots $2bn LAI Schizophrenia Franchise

    5 days ago | insights.citeline.com | Dean Rudge

    ‘Why Wouldn’t You Use This?’: Teva Plots $2bn LAI Schizophrenia Franchise Israeli Firm Eyeing Potential To Treat A Further 125,000 Patients In USTeva has laid out an ambitious goal for its long-acting injectable schizophrenia drugs to grow into a $2bn franchise, ahead of the planned US filing of olanzapine later this year.

  • What’s Next? Five Things To Look Out For In June

    6 days ago | insights.citeline.com | Dean Rudge

    What’s Next? Five Things To Look Out For In JuneGenerics Bulletin previews the most noteworthy and anticipated events for June 2025. Source: Norstella/Citeline

  • ‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

    1 week ago | insights.citeline.com | Dean Rudge

    ‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027Israeli Firm Plans To Double Revenues With Five Near-Term LaunchesTeva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

  • Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

    1 week ago | insights.citeline.com | Dean Rudge

    Alvotech And Advanz Add Three More In €160m EU Partnership ExpansionProposed Biosimilars To Ilaris (canakinumab) and Kesimpta (ofatumumab) IncludedFresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
39
Tweets
73
DMs Open
No
Dean Rudge
Dean Rudge @GbDeanR
2 Dec 24

To quote @NilePowerRanger 'When your is money long, all is possible.' Wow.

TURKI ALALSHIKH
TURKI ALALSHIKH @Turki_alalshikh

One of the greatest cards ever on February 22 in Riyadh 🥊🔥 #BigTime #RiyadhSeason https://t.co/4jQEowMXvD

Dean Rudge
Dean Rudge @GbDeanR
19 Oct 24

Never deleting this app

Mithras
Mithras @Tauroctonia

This is what the ethnogenesis of the English looked like in 550AD. A cheerful and stout Germanic Saxon ceorl and his doting Brythonic Celtic wife.

Dean Rudge
Dean Rudge @GbDeanR
30 Aug 24

Happy Friday Blue Noses.

John Percy
John Percy @JPercyTelegraph

Bloody hell, Birmingham City. Bid of around £9-10m has gone in for #Fulham striker Jay Stansfield, who scored 13 goals for Birmingham on loan last season. Blues trying to do a deal before the deadline: will be the most expensive signing ever in League One by a distance #bcfc #kro